- First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease (NERD)1
- New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high health care resource utilization, real world treatment patterns in newly diagnosed patients and diagnostic accuracy of grading disease severity, to be presented2,3,4
FLORHAM PARK, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple studies for its first-in-class treatment VOQUEZNA (vonoprazan) including an oral presentation at Digestive Disease Week (DDW) 2024, being held May 18-21 in Washington, D.C.